US.INCY · Incyte

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.771670555699594,
        "turnoverUsdM": 170.880528,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 109.2958,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 2.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.5,
      "take_profit_price": 122.7175,
      "target_multiplier": 1.9,
      "technical_strength": 1.73,
      "take_profit_percent": 6.1
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.543341111399188,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 115.0745,
    "ma50": 121.2636,
    "close": 115.71,
    "prevClose": 116.93,
    "avgVolume20": 1757000,
    "volumeRatio": 0.84,
    "changePercent": -1.04
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.023348368267444908,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.8469565367002073,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.5372151301753337,
      "volat_points": 0,
      "day_range_pct": 0.015124016938898973,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 20.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69,
        "contribution": 20.7
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 58.1,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 20.7/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 11.6,
      "市場環境": 6.2,
      "情緒分析": 6,
      "技術信號": 20.7,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 170.880528,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 735.23500335,
                "ma50": 725.8121993399999,
                "name": "QQQ",
                "close": 704.40002,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1504974000001,
                "ma50": 767.8083956999998,
                "name": "SPY",
                "close": 759.96997,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.771670555699594,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143168875,
                "url": "https://finnhub.io/api/news?id=f66dcbf25511a08b878438d105c6c1273bf9472aed9001c951afe82ace8015fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has logged a strong multi year share price performance, and the question now is whether the business can back up that move with the cash flows needed to justify today’s valuation. Over the past 3 years, Incyte has returned 120.2%, which puts a lot of weight on whether the underlying cash generation truly supports that kind of share price gain. Fresh oncology trial collaborations and upcoming late stage data readouts may shape expectations for how quickly Incyte can turn its pipeline...",
                "category": "company",
                "datetime": 1792883466,
                "headline": "Is Incyte (INCY) Cheap After A 120% Three Year Run?"
              },
              {
                "id": 143164998,
                "url": "https://finnhub.io/api/news?id=388201996321e281f0ec8ea9eeb99c36b5c25dc98a77ca405db13104321e5b7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte co funding and supplying its KRAS G12D inhibitor. The partnership gives Incyte deeper exposure to gastrointestinal oncology through a KRAS targeted combination approach, timed alongside fresh oncology data at the ESMO 2026 Congress that can shape...",
                "category": "company",
                "datetime": 1792854973,
                "headline": "Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?"
              },
              {
                "id": 143163693,
                "url": "https://finnhub.io/api/news?id=ca7e61755e0b25a11b06334d1f4ebde1210d7747635539d931cc266851b6a2e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer. The study will test a combination of Genmab’s bispecific antibody with Incyte’s selective KRAS G12D inhibitor in first-line treatment settings. The collaboration adds a fresh colorectal cancer program to Incyte’s pipeline that focuses on a mutation frequently found in these patients. The new KRAS G12D metastatic colorectal cancer trial is important, but it...",
                "category": "company",
                "datetime": 1792847685,
                "headline": "Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration"
              },
              {
                "id": 143163694,
                "url": "https://finnhub.io/api/news?id=dee0876997026439d069f641d5dc9a7f95c60c3beddf6cd7f1cf96e7d8454ab2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus as it prepares to present new oncology data at the European Society for Medical Oncology Congress in Madrid, covering several high-need solid tumor programs. That interest is landing on a stock that has been choppy in the short term but strong over longer periods, with Incyte’s 30 day share price return down 7.16% even as the year to date move sits at a 14.09% gain and the 3 year total shareholder return reaches 120.23%. This suggests sentiment has cooled...",
                "category": "company",
                "datetime": 1792843784,
                "headline": "Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?"
              },
              {
                "id": 143102825,
                "url": "https://finnhub.io/api/news?id=d3268d264beebe90b9d0e353e25fd0084e5e62a639d6ee1cbfa456cc3c409b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792674011,
                "headline": "Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 142562095,
                "url": "https://finnhub.io/api/news?id=4475fc6448f9a8a411761970f0b1b559fc63c7dee7dd75dda31557be570b512d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1790883187,
                "headline": "Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment"
              },
              {
                "id": 142521143,
                "url": "https://finnhub.io/api/news?id=d0d36b7cd2ff25dc25a458e3cd0397722758290b66be7129ef682d8beb405b0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY vs. TECH: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1790779202,
                "headline": "INCY or TECH: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142512990,
                "url": "https://finnhub.io/api/news?id=ebb9e8bd99a1dd17ab44f34bc85f9b82e7d59f57be8b09a67242ba3f904b7872",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.",
                "category": "company",
                "datetime": 1790768482,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup"
              }
            ],
            "raw_source": [
              {
                "id": 143180040,
                "url": "https://finnhub.io/api/news?id=84b37130b740a407253c921c88b9a01b2fd74fac728a63bf568099b4e7ed86e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant investigator-sponsored trial in Singapore, Chief Strategy Officer Mickael Chane-Du said during a Chardan conferen",
                "category": "company",
                "datetime": 1792922522,
                "headline": "Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer"
              },
              {
                "id": 143168875,
                "url": "https://finnhub.io/api/news?id=f66dcbf25511a08b878438d105c6c1273bf9472aed9001c951afe82ace8015fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has logged a strong multi year share price performance, and the question now is whether the business can back up that move with the cash flows needed to justify today’s valuation. Over the past 3 years, Incyte has returned 120.2%, which puts a lot of weight on whether the underlying cash generation truly supports that kind of share price gain. Fresh oncology trial collaborations and upcoming late stage data readouts may shape expectations for how quickly Incyte can turn its pipeline...",
                "category": "company",
                "datetime": 1792883466,
                "headline": "Is Incyte (INCY) Cheap After A 120% Three Year Run?"
              },
              {
                "id": 143164998,
                "url": "https://finnhub.io/api/news?id=388201996321e281f0ec8ea9eeb99c36b5c25dc98a77ca405db13104321e5b7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte co funding and supplying its KRAS G12D inhibitor. The partnership gives Incyte deeper exposure to gastrointestinal oncology through a KRAS targeted combination approach, timed alongside fresh oncology data at the ESMO 2026 Congress that can shape...",
                "category": "company",
                "datetime": 1792854973,
                "headline": "Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?"
              },
              {
                "id": 143163693,
                "url": "https://finnhub.io/api/news?id=ca7e61755e0b25a11b06334d1f4ebde1210d7747635539d931cc266851b6a2e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer. The study will test a combination of Genmab’s bispecific antibody with Incyte’s selective KRAS G12D inhibitor in first-line treatment settings. The collaboration adds a fresh colorectal cancer program to Incyte’s pipeline that focuses on a mutation frequently found in these patients. The new KRAS G12D metastatic colorectal cancer trial is important, but it...",
                "category": "company",
                "datetime": 1792847685,
                "headline": "Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration"
              },
              {
                "id": 143163694,
                "url": "https://finnhub.io/api/news?id=dee0876997026439d069f641d5dc9a7f95c60c3beddf6cd7f1cf96e7d8454ab2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus as it prepares to present new oncology data at the European Society for Medical Oncology Congress in Madrid, covering several high-need solid tumor programs. That interest is landing on a stock that has been choppy in the short term but strong over longer periods, with Incyte’s 30 day share price return down 7.16% even as the year to date move sits at a 14.09% gain and the 3 year total shareholder return reaches 120.23%. This suggests sentiment has cooled...",
                "category": "company",
                "datetime": 1792843784,
                "headline": "Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?"
              },
              {
                "id": 143160750,
                "url": "https://finnhub.io/api/news?id=4e18390fcefc656ee6841da30631e6a7b9b8f57e61afe7293177497e1a51c9ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi",
                "category": "company",
                "datetime": 1792839660,
                "headline": "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"
              },
              {
                "id": 143160751,
                "url": "https://finnhub.io/api/news?id=0e882632a27569fb2b48d1af01c22c55f344b73ff10a811fdd3089acaa730c41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer",
                "category": "company",
                "datetime": 1792839600,
                "headline": "Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"
              },
              {
                "id": 143137021,
                "url": "https://finnhub.io/api/news?id=ee9914d7c012c3940106e13b79be6b379e8b83bc1f66908de6edc2f5b0d147e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots",
                "category": "company",
                "datetime": 1792786277,
                "headline": "How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs"
              },
              {
                "id": 143136365,
                "url": "https://finnhub.io/api/news?id=4096afeeab360911f0fd6be6f61127974edc9434f479a10014bbe6db6d27b373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792776565,
                "headline": "Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?"
              },
              {
                "id": 143133387,
                "url": "https://finnhub.io/api/news?id=b9b049873c2f2cfb6a924d0a973a7fc71a29ff3583cd16b61c6a97bdb71bc0d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.",
                "category": "company",
                "datetime": 1792758300,
                "headline": "Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?"
              },
              {
                "id": 143133547,
                "url": "https://finnhub.io/api/news?id=772806fd053104a668901b32faf54bf45e0835695b33e1dc35a9d3f2fbeb914e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots",
                "category": "company",
                "datetime": 1792756851,
                "headline": "How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs"
              },
              {
                "id": 143132540,
                "url": "https://finnhub.io/api/news?id=0f45093d94ec333a4be247452f42dd718663748de09ef2fe4a2489fc37f5844d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "SOUTH SAN FRANCISCO, Calif., October 23, 2026--Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Vent",
                "category": "company",
                "datetime": 1792753200,
                "headline": "Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies"
              },
              {
                "id": 143112343,
                "url": "https://finnhub.io/api/news?id=13e30b993ab5b790cfd37f0c4ba95340af7716d65a8b88b96c059cc0978f4a09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.",
                "category": "company",
                "datetime": 1792724524,
                "headline": "Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option"
              },
              {
                "id": 143100702,
                "url": "https://finnhub.io/api/news?id=6ab780a131163289447ef0b1c9c349df35ff6aa647d1384ff08d7f769d8449af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Investing.com -- TD Cowen has identified seven biotech stocks as top picks for the fourth quarter, following a turbulent period that saw the sector retreat from August highs despite what the firm characterizes as solid underlying fundamentals.",
                "category": "company",
                "datetime": 1792676089,
                "headline": "TD Cowen Names Top Biotech Stocks for Q4 Amid Market Volatility"
              },
              {
                "id": 143102825,
                "url": "https://finnhub.io/api/news?id=d3268d264beebe90b9d0e353e25fd0084e5e62a639d6ee1cbfa456cc3c409b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792674011,
                "headline": "Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 143102035,
                "url": "https://finnhub.io/api/news?id=5eeeaba459ae3d16fd16969b9f569f2fb30e022b5f8afd6df5aef06b51d13d94",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "TD Cowen  analyst Tara Bancroft   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.",
                "category": "company",
                "datetime": 1792580258,
                "headline": "TD Cowen Maintains Buy on Incyte, Raises Price Target to $140"
              },
              {
                "id": 143036037,
                "url": "https://finnhub.io/api/news?id=30f63c6b342f081d573a977ff03988b6c8ab2d7237b1dd6dd44ca651ef06d703",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time",
                "category": "company",
                "datetime": 1792544172,
                "headline": "Why Should You Think About Vertex Differently Now?"
              },
              {
                "id": 143030752,
                "url": "https://finnhub.io/api/news?id=8cc4bfdd676b228f8ba3fc65c35aa8a8c4f3620c5024eca6793f5550e06fc505",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2234007364/image_2234007364.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation shares ESMO 2026 highlights: KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOE—click for more on INCY stock.",
                "category": "company",
                "datetime": 1792507236,
                "headline": "Incyte: Digesting The ESMO Updates In Pancreatic, Colorectal, And Ovarian Cancer"
              },
              {
                "id": 143021300,
                "url": "https://finnhub.io/api/news?id=d1786d0d7ca5d98a579ef8a2aab961bddd64cd5b97fb99597ba1da230dce5acb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "-- Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex -- Dr. Sandor brings more than 20 years of oncology clinical development experience, including leading programs to regulatory approval at Array BioPharma, Incyte and AstraZeneca -- Appointments strengthen the Board as Mestag evaluates MST-0312 in the Phase 1 STARLYS trial, currently enrolling patients with advanced solid",
                "category": "company",
                "datetime": 1792481400,
                "headline": "Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors"
              },
              {
                "id": 143011128,
                "url": "https://finnhub.io/api/news?id=271b5e852c06f359c09ed00199e48b180f7b6a0035a083b25dc80789f13c66cc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2296904068/image_2296904068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Merck KGaA is to buy Silence Therapeutics plc for $1.3B cash at $20/ADS (130% premium). Click for a look at SLN and see why I am downgrading it.",
                "category": "company",
                "datetime": 1792430596,
                "headline": "Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA"
              },
              {
                "id": 142989865,
                "url": "https://finnhub.io/api/news?id=93a8c9119aaa67ffa3172ec07711b3b51ab2b33c5e500d92b0e633bb72ab4416",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., October 18, 2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026",
                "category": "company",
                "datetime": 1792361100,
                "headline": "Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026"
              },
              {
                "id": 142948217,
                "url": "https://finnhub.io/api/news?id=4a8c8c9621f947a4a62916a447dab08d73f51aef50510b5232cf85928ee29516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
                "category": "company",
                "datetime": 1792160379,
                "headline": "2 High-Flying Stocks with Competitive Advantages and 1 We Question"
              },
              {
                "id": 142945202,
                "url": "https://finnhub.io/api/news?id=55d3a7b6cabe053e505c61a30150706fe99005e2606ecc029b17f6d0a0c813e0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Atopic-Dermatitis-Photo-via-Shutterstock.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.",
                "category": "company",
                "datetime": 1792073162,
                "headline": "Why Is Arcutis Biotherapeutics Stock Surging Thursday?"
              },
              {
                "id": 142918121,
                "url": "https://finnhub.io/api/news?id=0c60b7251adfe2eb346ee7992ddbd59053c051aa0e0a3820ebbfd95d49f0a24f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Truist Securities  analyst Srikripa Devarakonda   maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.",
                "category": "company",
                "datetime": 1791984605,
                "headline": "Truist Securities Maintains Hold on Incyte, Raises Price Target to $115"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142850332,
                "url": "https://finnhub.io/api/news?id=50d834f420411987405f297f0986958a6aa7e034de3dbdf9361db3bcef17ae1f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.",
                "category": "company",
                "datetime": 1791873418,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target"
              },
              {
                "id": 142824238,
                "url": "https://finnhub.io/api/news?id=bacaa0760479e8077018a44bda1ddb5821f5553ec0790d93f15b431d02fb26f7",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "After the closing bell on Monday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.",
                "category": "company",
                "datetime": 1791839101,
                "headline": "Discover the top S&P500 movers in Monday's after-hours session."
              },
              {
                "id": 142764205,
                "url": "https://finnhub.io/api/news?id=78f2a1b20a92c2f2664cbf93a4df03d907ffde640be59eabf97e4f652329c59c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.",
                "category": "company",
                "datetime": 1791560209,
                "headline": "Is Vertex Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142765501,
                "url": "https://finnhub.io/api/news?id=36685ffd3e97ab8486e6f47bfc46d2ef5b32cd0ec6791a1304605903a25a0dcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte will report its third-quarter earnings soon, with analysts forecasting a steep triple-digit plunge in its bottom line compared with the year-ago quarter.",
                "category": "company",
                "datetime": 1791542538,
                "headline": "What to Expect From Incyte’s Next Quarterly Earnings Report"
              },
              {
                "id": 142727790,
                "url": "https://finnhub.io/api/news?id=2bfd1260a045cbe27416cef5f31ccc79995d53168e565cea6a6d4091f496879d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., October 08, 2026--3Q26 Earnings Announcement",
                "category": "company",
                "datetime": 1791460800,
                "headline": "Incyte to Report Third Quarter Financial Results"
              },
              {
                "id": 142728523,
                "url": "https://finnhub.io/api/news?id=4ac2c471ac34036e3b4008229d81fb13b326c1db44af51577b296f015cd224b9",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.",
                "category": "company",
                "datetime": 1791453844,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114"
              },
              {
                "id": 142728524,
                "url": "https://finnhub.io/api/news?id=765938f016dda6652337e3c2097f957bd9f125fe38be302d57ab41e9d3146b45",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of $22.70 billion.",
                "category": "company",
                "datetime": 1791395120,
                "headline": "If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 142662169,
                "url": "https://finnhub.io/api/news?id=d3f58a3ce0b6e2bf9f405a09dff1ad258cfd1f49c4f14b7aa009c191bf96a04f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (\"Knight\") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1 “For patients living with chronic",
                "category": "company",
                "datetime": 1791286500,
                "headline": "Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil"
              },
              {
                "id": 142636275,
                "url": "https://finnhub.io/api/news?id=074b879f086129c8c62250751445aac9ea31a435c0d99b017957e8be236fa113",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Stifel  analyst Stephen Willey   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.",
                "category": "company",
                "datetime": 1791184316,
                "headline": "Stifel Maintains Buy on Incyte, Raises Price Target to $157"
              },
              {
                "id": 142562095,
                "url": "https://finnhub.io/api/news?id=4475fc6448f9a8a411761970f0b1b559fc63c7dee7dd75dda31557be570b512d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1790883187,
                "headline": "Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment"
              },
              {
                "id": 142588720,
                "url": "https://finnhub.io/api/news?id=cf47e1d66b6cbc95eefdae0dd23bf89024b00365a4523494f88a0fe630bacc8b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.",
                "category": "company",
                "datetime": 1790877638,
                "headline": "If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 142557475,
                "url": "https://finnhub.io/api/news?id=d651d67aff3fb4f7e7c9ca6edda101b005d21406b80e151cc62e9a1a8627ec8e",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Wells Fargo  analyst Derek Archila   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.",
                "category": "company",
                "datetime": 1790843575,
                "headline": "Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128"
              },
              {
                "id": 142521143,
                "url": "https://finnhub.io/api/news?id=d0d36b7cd2ff25dc25a458e3cd0397722758290b66be7129ef682d8beb405b0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY vs. TECH: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1790779202,
                "headline": "INCY or TECH: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142512990,
                "url": "https://finnhub.io/api/news?id=ebb9e8bd99a1dd17ab44f34bc85f9b82e7d59f57be8b09a67242ba3f904b7872",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.",
                "category": "company",
                "datetime": 1790768482,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup"
              },
              {
                "id": 142468441,
                "url": "https://finnhub.io/api/news?id=c66772dfe3ee69a70fa76f2ec8797d2c4507466e9205bbc48d9e0224ef01e94c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.",
                "category": "company",
                "datetime": 1790606700,
                "headline": "MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy"
              },
              {
                "id": 142468169,
                "url": "https://finnhub.io/api/news?id=9ad50950f9b05da2510f7ec51b6f364ba10619157b26b3adf3c6882330aaa6d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.",
                "category": "company",
                "datetime": 1790604180,
                "headline": "LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss"
              },
              {
                "id": 142496785,
                "url": "https://finnhub.io/api/news?id=b0321508ca7458c7703eb8f5a78166f3b934a58362f2be1e62b5becfdf34fc96",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.",
                "category": "company",
                "datetime": 1790602585,
                "headline": "JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123"
              },
              {
                "id": 142496786,
                "url": "https://finnhub.io/api/news?id=955439cb6c2933ce5d22d366515ce2ead7b8027540c649b33b1e2244368d4cf6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Balding-Man-Showing-His-Head-With-Thin-H.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.",
                "category": "company",
                "datetime": 1790600073,
                "headline": "FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss"
              },
              {
                "id": 142466645,
                "url": "https://finnhub.io/api/news?id=12d9e67f1e1f5fb300b04e70799f6f27112241cb27815fdc45b06f74553858db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar",
                "category": "company",
                "datetime": 1790599105,
                "headline": "Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment"
              },
              {
                "id": 142467335,
                "url": "https://finnhub.io/api/news?id=78bdb57e04871ecb34909a65606c74a31535191982b93c57cba49eb178fbc568",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.",
                "category": "company",
                "datetime": 1790576925,
                "headline": "HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152"
              },
              {
                "id": 142463061,
                "url": "https://finnhub.io/api/news?id=ec1a24189f67ee162e36de4447d0ec890cc341b591464fb0ec8cbadece6aa492",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2295578501/image_2295578501.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.",
                "category": "company",
                "datetime": 1790572953,
                "headline": "Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases"
              },
              {
                "id": 142427042,
                "url": "https://finnhub.io/api/news?id=35a7a53435f6293704a9963de0e5dbe152bf4b44a46b7ad6f183aa81df7508ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva",
                "category": "company",
                "datetime": 1790377200,
                "headline": "Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva"
              },
              {
                "id": 142425658,
                "url": "https://finnhub.io/api/news?id=6b7cf0c329c8dc9bb5e2734373f8103650936b92a03c025e34b722532dbf4167",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.",
                "category": "company",
                "datetime": 1790361817,
                "headline": "INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill"
              },
              {
                "id": 142437357,
                "url": "https://finnhub.io/api/news?id=87de46760052dac2d262596b39e8957ee92e0233ae78bcefc82787bc209b1f20",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva",
                "category": "company",
                "datetime": 1790348028,
                "headline": "FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 49,
            "discarded_article_count": 40
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.7,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.3,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.3,
            "vcp_reason": "波幅收縮(18.1%→8.1%)；跌縮量(近10日3日)；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1722966.6666666667,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 1675270,
              "avg_vol_20": 1743655,
              "avg_vol_30": 1722966.6666666667,
              "range_pct_10": 0.08115115374643506,
              "range_pct_20": 0.15867254342753437,
              "range_pct_30": 0.18096966554316826,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9723171274352377,
              "dist_to_20d_high": 0.0826859045504995,
              "down_shrink_days": 3,
              "breakout_level_20d": 126.14,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.44842406876790836
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.771670555699594,
              "turnoverUsdM": 170.880528,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 109.2958,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 2.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.5,
            "take_profit_price": 122.7175,
            "target_multiplier": 1.9,
            "technical_strength": 1.73,
            "take_profit_percent": 6.1
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.543341111399188,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.INCY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 3.2071,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.77
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 14.86
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.2063
    },
    "kdj": {
      "d": 66.69,
      "j": 102.7,
      "k": 78.69,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 52.52
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -20413500,
      "recentSlope": 152620,
      "previousSlope": -1328780
    },
    "rsi": 53.39,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 108.5061,
      "position": "SAR喺價下",
      "distancePct": 6.23,
      "previousTrend": "上升"
    },
    "ma50": 121.2636,
    "macd": {
      "macd": -1.861249778506874,
      "trend": "看漲",
      "signal": -2.502941387051938,
      "histogram": 0.6416916085450639
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 115.0844,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.84,
      "score": 4,
      "avgVolume": 1757000,
      "currentVolume": 1476800
    },
    "derived": {
      "ma20": 115.0745,
      "ma50": 121.2636,
      "prevClose": 116.93,
      "avgVolume10": 1710740,
      "avgVolume20": 1757000,
      "changePercent": -1.04,
      "avgVolumeForScore": 1757000
    },
    "ma_cross": {
      "ma20": 115.0745,
      "ma50": 121.2636,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 115.4835,
      "prevMa50": 121.3598,
      "spreadPct": 5.1,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 107.1798,
      "upper": 122.9692,
      "position": "上半部"
    },
    "rsi_short": 60.48,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.84
    }
  }
}

{
  "close": 115.71,
  "volume": 1476800,
  "changePercent": -1.04
}